Hydroxychloroquine associates with birth defects in early pr
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Hydroxychloroquine (HCQ) is generally considered safe in pregnancy for the treatment of rheumatic conditions, but studies have been too small to evaluate teratogenicity. Quantifying the risk of congenital malformations associated with early pregnancy exposure to HCQ is important both in the context of its ongoing use for rheumatological disorders as well as its potential future use for COVID-19 prophylaxis, for which a number of clinical trials are ongoing despite initial trials for COVID-19 treatment having been negative. The study was done to evaluate the risk of major congenital malformations associated with exposure to HCQ during the first trimester, the period of organogenesis.

The study included 2,045 HCQ exposed and 3,198,589 unexposed pregnancies continuously enrolled in their respective insurance program from 3 months before the last menstrual period through at least one month after delivery; infants were enrolled for at least 3 months after birth. Overall, 54.8 per 1,000 infants exposed to HCQ were born with a major congenital malformation versus 35.3 per 1,000 unexposed infants, corresponding to an unadjusted relative risk of 1.51. Patient characteristics were balanced in the restricted, propensity score-matched cohort. The adjusted relative risk was 1.26; it was 1.33 for a daily dose equal or more than 400mg and 0.95 for less than 400mg. Among the different malformation groups considered, more substantial increases in the risk for oral clefts, respiratory anomalies, and urinary defects were observed, although estimates were imprecise. No pattern of malformations was identified.

These findings suggest a small increase in the risk of malformations associated with first-trimester HCQ use. For most patients with autoimmune rheumatic disorders, the benefits of treatment during pregnancy will likely outweigh this risk. If HCQ were shown to be effective for COVID-19 prophylaxis in ongoing trials, the risk of malformations would need to be balanced against such benefits.

Source: https://www.ajog.org/article/S0002-9378(20)31064-4/fulltext?rss=yes
Dr. S●●●●●●A R●Y and 1 others like this1 share